Literature DB >> 12378521

Primary cutaneous large B-cell lymphoma of the leg: histogenetic analysis of a controversial clinicopathologic entity.

Marco Paulli1, Alessandra Viglio, Daniela Vivenza, Daniela Capello, Davide Rossi, Roberta Riboni, Marco Lucioni, Paolo Incardona, Emanuela Boveri, Mario Bellosta, Ester Orlandi, Giovanni Borroni, Mario Lazzarino, Emilio Berti, Elvio Alessi, Umberto Magrini, Gianluca Gaidano.   

Abstract

This study analyzes the pathologic and molecular features of 5 cases of primary cutaneous large B-cell lymphoma of the leg (PCLBCL-leg), recently included in the European Organization for Research and Treatment of Cancer (EORTC) classification of primary cutaneous lymphoma. PCLBCL-leg accounts for 5% to 10% of all primary cutaneous B-cell lymphoma (PCBCL), usually affects elderly patients and carries a worse prognosis than other forms of PCBCL. It has been proposed that the malignant cells of PCLBCL-leg originate from germinal center (GC)-related cells, but their effective normal counterpart is unclear, and the rationale behind the inclusion of this lymphoma as a separate entity is based on its prognosis rather than on its proved histogenesis. All of our cases of PCLBCL-leg morphologically resembled diffuse large B-cell lymphoma (DLBCL), but to better define their histogenesis, we also analyzed various phenotypic and genotypic markers, including mutations of the Ig and of BCL-6 genes, as well as expression of the bcl-6, MUM1, and CD138/syndecan-1 proteins. Immunohistochemically, all of our cases stained for the L-26/CD20cy and CD79a antigens and expressed the bcl-2, bcl-6, and MUM-1 proteins but were negative for both the CD10/CALLA and CD138 antigens. With respect to molecular analysis, the lymphoma population of all PCLBCL-leg carried hypermutation of Ig genes, and all but 1 case also harbored mutations of the BCL-6 gene. Our results indicate that PCLBCL-leg are similar both under the morphofunctional and molecular profiles to most DLBCL of other sites. Thus, caution seems justified before definitely considering PCLBCL of the leg as a distinct entity. Copyright 2002, Elsevier Science (USA). All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12378521     DOI: 10.1053/hupa.2002.126881

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  4 in total

Review 1.  [Aggressive primary cutaneous B-cell lymphomas and novel EBV+ entities].

Authors:  C Lamos; E Dippel
Journal:  Hautarzt       Date:  2017-09       Impact factor: 0.751

2.  Primary Cutaneous Large B-Cell Lymphoma, Leg Type, Localized on the Dorsum.

Authors:  A Patrizi; B Raone; E Sabattini; C Gurioli; A Pileri; C D'Acunto
Journal:  Case Rep Dermatol       Date:  2009-11-11

Review 3.  Approach to Cutaneous Lymphoid Infiltrates: When to Consider Lymphoma?

Authors:  Yann Vincent Charli-Joseph; Michelle Gatica-Torres; Laura Beth Pincus
Journal:  Indian J Dermatol       Date:  2016 Jul-Aug       Impact factor: 1.494

4.  Primary cutaneous B-cell lymphoma other than marginal zone: clinicopathologic analysis of 161 cases: Comparison with current classification and definition of prognostic markers.

Authors:  Marco Lucioni; Emilio Berti; Luca Arcaini; Giorgio A Croci; Aldo Maffi; Catherine Klersy; Gaia Goteri; Carlo Tomasini; Pietro Quaglino; Roberta Riboni; Mariarosa Arra; Elena Dallera; Vieri Grandi; Mauro Alaibac; Antonio Ramponi; Sara Rattotti; Maria Giuseppina Cabras; Silvia Franceschetti; Giulio Fraternali-Orcioni; Nicola Zerbinati; Francesco Onida; Stefano Ascani; Maria Teresa Fierro; Serena Rupoli; Marcello Gambacorta; Pier Luigi Zinzani; Nicola Pimpinelli; Marco Santucci; Marco Paulli
Journal:  Cancer Med       Date:  2016-09-26       Impact factor: 4.452

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.